Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors
- Author
- PORCELLI, L1 ; QUATRALE, A. E1 ; MANTUANO, P1 ; SILVESTRIS, N2 ; ROLLAND, J. F1 ; BIANCOLILLO, L1 ; PARADISO, A1 ; AZZARITI, A1
[1] Clinical Experimental Oncology Laboratory, National Cancer Research Center Giovanni Paolo II, Bari, Italy
[2] Medical and Experimental Oncology Unit, National Cancer Research Center Giovanni Paolo II, Bari, Italy - Issue title
- Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer
- Author (monograph)
- GIOVANNETTI, E (Editor)1 ; PETERS, G. J (Editor)1
[1] Dept. Medical Oncology, VU University Medical Center, Amsterdam, Netherlands - Source
Current pharmaceutical design (Print). 2013, Vol 19, Num 5, pp 918-926, 9 p ; ref : 93 ref
- ISSN
- 1381-6128
- Scientific domain
- Pharmacology drugs
- Publisher
- Bentham, Sharjah
- Publication country
- United Arab Emirates
- Document type
- Article
- Language
- English
- Author keyword
- EGFR biomarkers clinical trials combination therapy mTOR
- Keyword (fr)
- Antiangiogénique Anticancéreux Article synthèse Association médicamenteuse Essai clinique Homme Marqueur biologique Protéine mTOR Récepteur facteur croissance épiderme Traitement associé Anti-EGFR Inhibiteur mTOR
- Keyword (en)
- Antiangiogenic agent Antineoplastic agent Review Drug combination Clinical trial Human Biological marker Mammalian target of rapamycin Epidermal growth factor receptor Combined treatment Anti-EGFR mTOR inhibitor
- Keyword (es)
- Antiangiogenico Anticanceroso Artículo síntesis Asociación medicamentosa Ensayo clínico Hombre Marcador biológico Proteína mTOR Receptor del factor de crecimiento epidérmico Tratamiento asociado Anti-EGFR Inhibidor mTOR
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments
- Discipline
- General pharmacology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27353868
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.2174/138161213804547295 
https://dx.doi.org/10.2174/138161213804547295
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161213804547295\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:84:\"Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"918\";s:8:\"\u0000*\u0000epage\";s:3:\"926\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"PORCELLI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:14:\"QUATRALE, A. E\";i:1;s:11:\"MANTUANO, P\";i:2;s:13:\"SILVESTRIS, N\";i:3;s:13:\"ROLLAND, J. F\";i:4;s:14:\"BIANCOLILLO, L\";i:5;s:11:\"PARADISO, A\";i:6;s:11:\"AZZARITI, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:113:\"Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer\";s:8:\"\u0000*\u0000title\";s:84:\"Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161213804547295\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:84:\"Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"918\";s:8:\"\u0000*\u0000epage\";s:3:\"926\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"PORCELLI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:14:\"QUATRALE, A. E\";i:1;s:11:\"MANTUANO, P\";i:2;s:13:\"SILVESTRIS, N\";i:3;s:13:\"ROLLAND, J. F\";i:4;s:14:\"BIANCOLILLO, L\";i:5;s:11:\"PARADISO, A\";i:6;s:11:\"AZZARITI, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:113:\"Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer\";s:8:\"\u0000*\u0000title\";s:84:\"Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161213804547295\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161213804547295\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:84:\"Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"918\";s:8:\"\u0000*\u0000epage\";s:3:\"926\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"PORCELLI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:14:\"QUATRALE, A. E\";i:1;s:11:\"MANTUANO, P\";i:2;s:13:\"SILVESTRIS, N\";i:3;s:13:\"ROLLAND, J. F\";i:4;s:14:\"BIANCOLILLO, L\";i:5;s:11:\"PARADISO, A\";i:6;s:11:\"AZZARITI, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:113:\"Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer\";s:8:\"\u0000*\u0000title\";s:84:\"Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161213804547295\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:84:\"Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"918\";s:8:\"\u0000*\u0000epage\";s:3:\"926\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"PORCELLI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:14:\"QUATRALE, A. E\";i:1;s:11:\"MANTUANO, P\";i:2;s:13:\"SILVESTRIS, N\";i:3;s:13:\"ROLLAND, J. F\";i:4;s:14:\"BIANCOLILLO, L\";i:5;s:11:\"PARADISO, A\";i:6;s:11:\"AZZARITI, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:113:\"Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer\";s:8:\"\u0000*\u0000title\";s:84:\"Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161213804547295\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:84:\"Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"918\";s:8:\"\u0000*\u0000epage\";s:3:\"926\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"PORCELLI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:14:\"QUATRALE, A. E\";i:1;s:11:\"MANTUANO, P\";i:2;s:13:\"SILVESTRIS, N\";i:3;s:13:\"ROLLAND, J. F\";i:4;s:14:\"BIANCOLILLO, L\";i:5;s:11:\"PARADISO, A\";i:6;s:11:\"AZZARITI, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:113:\"Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer\";s:8:\"\u0000*\u0000title\";s:84:\"Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
